Antidepressant; Flesinoxan; Body temperature; Depression
Abstract :
[en] Flesinoxan is a highly potent and selective 5‐HT1A full agonist, active in several models of depression. In this pilot open study, flesinoxan (4 mg/d) was administered orally for 4 weeks in 16 major depressive, mostly treatment‐resistant inpatients exhibiting a score of at least 19 on the Hamilton depression sale. Weekly ratings included Hamilton depression scale, Montgomery and Asberg depression scale (MADRS), and Clinical Global Impressions (CGI). Results showed considerable improvement in depressive symptomatology with mean MADRS scores (SD) dropping from 35.7 (10–40) to 13.0 (11.9) and CGI‐illness severity from 5.69 (1.14) to 2.73 (1.62) after 4 weeks of treatment. Moreover, 13 patients were classified as much or very much improved on the CGI‐global improvement. The tolerance of flesinoxan was excellent, with only four patients exhibiting side‐effects. In contrast to acute studies with 5HT1A agonists, flesinoxan induced no significant decrease in daily oral temperature over the 4‐week period. In eight melancholic patients, the mean REM latency (SD) of respectively 35.6 (15.9) and 40.2 (17.9) min during two baseline nights significantly increased to 51.9 (20.9) min during a double‐blind challenge night with flesinoxan 1 mg as compared to 42.0 (16.1) min with placebo, and to respectively 55.6 (29.9) and 55.6 (30.2) min during the last two treatment nights. All these findings encourage further developments of flesinoxan as a promising antidepressant.
Disciplines :
Psychiatry
Author, co-author :
ANSSEAU, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale
PITCHOT, William ; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale
Gonzalez Moreno, Antonio; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale
Papart, Patrick ; Université de Liège - ULiège > Département des sciences cliniques > Psycho. quantitative - Psychiatrie légale et sociale
WAUTHY, Jacques ; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale
Language :
English
Title :
Pilot study of flesinoxan in major depression. Effect on REM latency and body temperature
Publication date :
1993
Journal title :
Human Psychopharmacology
ISSN :
0885-6222
eISSN :
1099-1077
Publisher :
John Wiley & Sons, Hoboken, United States - New Jersey
Anderson I.M., Cowen P.J., Grahame‐Smith D.G. (1990) The effect of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology 100:498-503.
Ansseau M., Kupfer D.J., Reynolds C.F. (1985) Internight variability of REM latency in major depression: implications for the use of REM latency as a biological correlate. Biological psychiatry 20:489-505.
Ansseau M., Lembreghts M., Pitchot W., Gonzalez Moreno A., Legros J.J., Bradford L.D. (1992) Neuroendocrine responses to intravenous flesinoxan as an index of serotonergic neurotransmission. Clinical Neuropharmacology 15:114B.
Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, 3rd edn, (revised)., Washington, DC; 1987.
De Roeck J., Cluydts R., Schotte C., Rouckhout D., Cosyns P. (1989) Explorative single‐blind study on the sedative and hypnotic effects of buspironein anxiety patients. Acta Psychiatrica Scandinavica 79:129-135.
De Voogd J.M., Prager G. (1987) Early clinical experience with flesinoxan, a new selective 5‐HT1A receptor agonist. Cardiovascular Pharmacology of 5‐Hydroxytryptamine , Saxena, P. R., Wallis, D. J., Wouters, W., Bevan, P., (Eds), Kluwer Academic Publishers, Dordrecht; 355-359.
Goodwin G.M., DeSouza R.J., Green A.R., Heal D.J. (1987) The pharmacology of the behavioural and hypothermic responses of rats to 8‐hydroxy‐2(di‐n‐propylamino)tetralin (8‐OHDPAT). Psychopharmacology 91:506-511.
ECDEU Assessment Manual for Psychopharmacology (revised), Guy, W., National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD; 1976.
Hamilton M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 12:56-62.
Heller A.H., Beneke M., Kuemmel B., Spencer D., Kurtz N.M. (1990) Ipsapirone: Evidence for efficacy in depression. Psychopharmacology Bulletin 26(2):219-222.
Hest van A., Drimmelen van M., Olivier B. (1992) Flesinoxan shows antidepressant activity in a DRL72s screen. Psychopharmacology 107:474-479.
Hjorth S. (1985) Hypothermia in the rat induced by the potent serotonergic agent 8‐OHDPAT. Journal of Neural Transmission 61:131-135.
Jenkins S.W., Robinson D.S., Fabre L.F., Andary J.J., Messina M.E., Reich L.A. (1990) Gepirone in the treatment of major depression. Journal of Clinical Psychopharmacology 10:77S-85S.
Kupfer D.J. (1976) REM latency: a psychobiologic marker for primary depressive disease. Biological Psychiatry 11:159-174.
Kupfer D.J., Shipley J.E., Perel J.M., Pollock B., Coble P.A., Spiker D.G. (1987) Antidepressants and EEG sleep: Search for specificity. Clinical Pharmacology in Psychiatry: Selectivity in Psychotropic Drug Action—Promises or Problems , Psychopharmacology Series 3, Dahl, S. G., Gram, L. F., Paul, S. M., Potter, W. Z., (Eds), Springer‐Verlag, New York; 167-173.
Kupfer D.J., Spiker D.G., Coble P.A., Neil J.F., Ulrich R., Shaw D.H. (1981) Sleep and treatment prediction in endogenous depression. American Journal of Psychiatry 138:429-434.
Lesch K.P., Poten B., Söhnle K., Schulte H.M. (1990) Pharmacology of the hypothermic response to 5‐HT1A receptor activation in humans. European Journal of Clinical Pharmacology 39:17-19.
Montgomery A., Asberg M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134:382-389.
Rechtstaffen A., Kales A.A. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages of Human Subjects, Public Health Service, US Government Printing Office, Washington DC; 1968.
Reynolds C.F., Taska L.S., Jarrett D.B., Coble P.A., Kupfer D.J. (1983) REM latency in depression: Is there one best definition?. Biological psychiatry 18:849-863.
Rickels K., Amsterdam J., Clary C., Hassman J., London J., Purruoli G., Schweizer E. (1990) Buspi‐one in depressed outpatients: A controlled study. Psychopharmacology Bulletin 26(2):163-167.
Shipper J., Tulp, Berkelmans B., Mos J., Heyden van der J.A.M., Olivier B. (1991) Preclinical pharmacology of flesinoxan: a potential anxiolytic and antidepressant drug. Human Psychopharmacology 6:553-561.
Wouters W., Hartog J., Bevan P. (1988) Flesinoxan. Cardiovascular Drug Review 6:71-83.